Dragonfly and AbbVie expand collaboration in oncology and autoimmune disease

Companies to develop additional drug candidates in immune-mediated diseases using Dragonfly's proprietary Tri-specific NK cell Engager Therapy (TriNKET) platform

Dragonfly Therapeutics yesterday announced an expansion of its research collaboration with AbbVie to discover and develop Dragonfly’s novel immunotherapies for new targets in auto-immune and fibrotic diseases. AbbVie licensed its first TriNKET drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019, in January 2021, Dragonfly Therapeutics notified in a statement.

Under the agreement, Dragonfly will grant AbbVie the option to license exclusive worldwide intellectual property rights to multiple new candidates developed using Dragonfly’s TriNKET technology platform. AbbVie will pay Dragonfly an upfront payment, future success-based milestone payments and royalties, the statement added.

AbbVieautoimmune disease treatmentDragonflyTriNKET technology
Comments (3)
Add Comment